Market Signal Briefing

SummaryBanc of California reported strong Q3 results, with net interest income up 5% and preferred dividends well covered by earnings.Loan loss provisions have normalized, and the loan book remains healthy, with most past-due loans backed by real estate collateral.BANC.PR.F preferred shares offer a 7.85% yield, trading below par, and will reset to a potentially higher rate in 2027 based on Treasury yields.The preferred shares present an attractive risk/reward profile for income-focused investors, given solid coverage and current valuation.Black Friday Sale 2025: Get 20% Off Juanmonino/iStock via Getty Images

Introduction Since my previous article on Banc of California (BANC) was published, I was able to pick up some of the bank's preferred shares at a discount to its par value. As I now have a long position in

Analyst’s Disclosure:I/we have a beneficial long position in the shares of BANC.PR.F either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

I may add to my position in the near future

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

For those with decades left in their investing journey, these top healthcare stocks could be worthy portfolio contenders.

If you have a 20-year time horizon for your investments, you might tend to favor a wide range of stocks that fit into various categories, such as growth stocks, value stocks, and dividend stocks. The healthcare industry is one example of a sector that presents the opportunity to find stocks that fit into one or all of these categories, all while allowing you to build a position in compelling businesses benefiting from powerful secular tailwinds.

Here are two such healthcare stocks which fit the bill that you might want to consider adding to your buy list in the near term.

Image source: Getty Images.

1. Pfizer
Pfizer (PFE +2.46%) has dealt with some major changes as a company in the last several years. In the years leading up to the pandemic, Pfizer's growth was slow, and its revenue growth was in the low single digits. The success of the COVID-19 vaccine, developed with its German partner BioNTech, brought a massive and unprecedented era of growth for the business.

To bolster its drug pipeline and offset upcoming patent expirations (for key drugs like Eliquis and Ibrance), Pfizer used the extensive stockpile of profits and cash it gained from its COVID-19 products to pursue numerous acquisitions. For example, the $43 billion acquisition of Seagen in 2023 was pivotal to its ongoing oncology expansion and added several high-potential cancer therapies to its portfolio.

Following its acquisition of Seagen, Pfizer gained four approved oncology drugs: Adcetris, Padcev, Tivdak, and Tukysa. These products treat various cancers, including lymphoma, bladder, cervical, breast, and colorectal cancers.

The company has commercialized several other new products in the last several years, including RSV vaccine Abrysvo, cancer medicine Elrexfio, and alopecia treatment Litfulo. The migraine treatment Nurtec, ulcerative colitis treatment Velsipity, and the meningococcal vaccine Penbraya are also newer additions to Pfizer's portfolio from both internal development and acquisitions that are expected to drive future growth as they gain traction in the market.

Today's Change

(

2.46

%) $

0.60

Current Price

$

25.00

The company is actively focusing its resources on non-COVID growth areas, including oncology, vaccines, and cardiometabolic treatments. Pfizer also recently announced the acquisition of biotech Metsera in a deal valued at up to $10 billion. This move is a significant strategic pivot for Pfizer to counter a shrinking COVID-19 franchise and looming patent expirations. It also gives Pfizer a pipeline of obesity drug candidates, including a once-monthly GLP-1 injection that showed promise in early studies.

In the first nine months of 2025, Pfizer reported total revenue of about $45 billion, a slight decline from the same period in 2024. However, generally accepted accounting principles (GAAP) net income rose 24% year over year in the nine-month period to $9.4 billion. Pfizer is still on track to deliver approximately $7.2 billion in net cost savings by the end of 2027. This is part of an ongoing savings initiative launched in late 2023.

The company remains a faithful dividend payer. Pfizer delivered more than $7 billion in cash dividends to shareholders in the first nine months of 2025. It has a long history of paying dividends, and has made 348 consecutive quarterly payments while increasing its dividend annually for 16 consecutive years. That yield is now close to 7%, given the pressure that shares have experienced of late.

This top healthcare stock has a strong financial foundation and a burgeoning pipeline on top of its impressive product portfolio. For long-term investors, waiting through this transitional period post-pandemic and as patent losses loom (a normal part of the life cycle for every pharmaceutical drug) could be a rewarding experience as Pfizer's share price and dividend grows in the coming decades.

2. Viking Therapeutics
Viking Therapeutics (VKTX 0.03%) is a clinical-stage biopharmaceutical company, so its value is almost entirely dependent on successful clinical trial outcomes and regulatory approval. That said, if you have a 20-year buy-and-hold horizon and the sufficient personal risk tolerance level for your portfolio, Viking Therapeutics could be a compelling option for several reasons.

Viking's lead candidate, VK2735, has shown promising results in early-stage clinical trials for significant weight loss and improvements for diabetes patients. If it successfully completes phase 3 trials and gains FDA approval, it could capture a share of the rapidly expanding obesity and diabetes drug markets. Like Eli Lilly's Zepbound and Mounjaro, VK2735 targets both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.

This dual action may offer better overall health improvements and greater weight reduction compared to existing single-target (GLP-1 only) drugs like Novo Nordisk's Wegovy and Ozempic. Viking is developing VK2735 in two formulations: injectable and oral. An effective and well-tolerated oral pill would offer a significant convenience advantage over injections that would appeal to a large segment of patients who prefer to avoid needles.

Today's Change

(

-0.03

%) $

-0.01

Current Price

$

34.26

The injectable version is in phase 3 trials, and could offer the potential for a less frequent, once-a-month maintenance dose due to its long half-life. In early trials, the injectable formulation demonstrated a significant mean body weight reduction on top of a favorable safety profile, and low discontinuation rates.

In the phase 2 VENTURE study, which involved 176 adults with obesity, the injectable formulation demonstrated a statistically significant mean body weight reduction of up to 14.7% from baseline after 13 weeks of once-weekly dosing with the highest dose. This early efficacy data positions it competitively against current market leaders, though longer-term phase 3 data will be necessary to confirm overall efficacy compared to the 68-to-72-week data available for existing, established treatments.

Beyond VK2735, Viking has other promising drug candidates in its pipeline. This includes VK2809 for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with a large potential market, and VK0214 for the rare condition X-linked adrenoleukodystrophy (X-ALD).

A diversified pipeline could reduce the company's reliance on a single product's success in the future. Viking Therapeutics has a robust cash position, and ended Q3 2025 with over $715 million in cash, cash equivalents, and short-term investments as of the end of the quarter. Management believes its current capital position is sufficient to fund its operations through completion of the phase 3 trials for VK2735.

This cash stockpile should provide a measure of stability to continue the company's extensive research and development initiatives without immediate, dilutive fundraising concerns. If you like this business and where its foothold could extend in the lucrative but still nascent GLP-1 market, Viking Therapeutics looks like an intriguing buy-and-hold stock for risk-tolerant investors.

Burt Flickinger offers a bleak outlook for retail this holiday season, noting that most consumers are financially stretched. He points to a significant divergence in performance, with retailers like Walmart (WMT), TJX Companies (TJX), BJ's Wholesale (BJ), and Costco (COST) thriving.

Shares of the top cruise line operator have climbed 172% in three years.

Shares of Carnival (CCL +4.90%) have bounced back in remarkable fashion. In the past three years, they have soared 172% (as of Nov. 18). The market has become optimistic thanks to impressive financial results that indicate the business is operating from a better position these days.

Investors are right to wonder if the momentum will continue. Before buying this travel stock, continue reading to learn more about the company.

A Carnival vessel. Image source: Carnival.

Carnival benefits from industry tailwinds
It seems that a quarter doesn't go by when Carnival doesn't report records in key metrics. In the third quarter, the company posted record revenue, net yields, and customer deposits. These signs all point to solid demand for cruise travel, which is certainly welcome news following the temporary disruption caused by the pandemic.

Investors can have confidence in the long-term picture, believing that Carnival is in position to generate durable growth. The cruise market today only represents a tiny sliver of the worldwide vacation market. The industry is also attracting younger and first-time cruise travelers, expanding its demographic.

Rising profits are helping to improve the financial picture
During the fiscal 2025 third quarter, Carnival reported $2.3 billion in operating income. This was up 4% year over year, which isn't too exciting. However, that profitability metric is better than the $279 million loss in the same period of 2022. The company's bottom line has drastically improved since the depths of the health crisis.

Today's Change

(

4.90

%) $

1.24

Current Price

$

26.56

Management is taking advantage of the situation to clean up Carnival's balance sheet. Long-term debt, which totals $26.5 billion, is decreasing. With ongoing refinancing activity, the business has seen upgrades from the three major bond rating agencies.

This isn't to say that Carnival is home safe just yet. The company's market cap is $33.6 billion, so to see a debt load that's almost 80% of that might be troubling to those investors who desire their holdings to be in a much stronger financial position. However, the positive trend is undeniable. The company is definitely sailing in the right direction.

Should investors be worried about a recession?
Any company that depends on discretionary spending will undoubtedly be hurt in a possible recessionary scenario. Carnival falls into this category. Should the economy take a turn for the worse, consumers will surely tighten up their purse strings and be more discerning with how they spend their money.

This poses a risk. Carnival appears to be in solid shape, but there's a chance that its revenue will take a hit, and earnings will fall. What's more, the business could be forced to raise capital. These issues should be short-lived, though.

, /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that an amended securities class action lawsuit has been filed against CarMax, Inc. ("CarMax") (NYSE: KMX) which expands the class period to include those who purchased or otherwise acquired CarMax securities between June 20, 2025, and November 5, 2025, inclusive (the "Class Period"). The lead plaintiff deadline is January 2, 2026.

CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:
If you suffered CarMax losses, you may CLICK HERE or copy and paste the following link into your browser: https://www.ktmc.com/new-cases/carmax-inc?utm_source=PR_Newswire&mktm=PR

You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected]. 

DEFENDANTS' ALLEGED MISCONDUCT:
The complaint alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Defendants recklessly overstated CarMax's growth prospects when, in reality, its earlier growth in the 2026 fiscal year was a temporary benefit from customers buying cars due to speculation regarding tariffs; and (2) as a result, Defendants' positive statements about the company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Please CLICK HERE to view our video or copy and paste this link into your browser: https://youtu.be/6jH2v28HBaU 

THE LEAD PLAINTIFF PROCESS:
CarMax investors may, no later than January 2, 2026, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

Kessler Topaz Meltzer & Check, LLP encourages CarMax investors who have suffered significant losses to contact the firm directly to acquire more information.

CLICK HERE TO SIGN UP FOR THE CASE OR GO TO: https://www.ktmc.com/new-cases/carmax-inc?utm_source=PR_Newswire&mktm=PR 

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP:
Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com.

CONTACT:
Kessler Topaz Meltzer & Check, LLP
Jonathan Naji, Esq.
(484) 270-1453
280 King of Prussia Road
Radnor, PA 19087
[email protected] 

May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.

SOURCE Kessler Topaz Meltzer & Check, LLP

Silver Range Resources Ltd (TSX-V:SNG, OTC:SLRRF) CEO Mike Power talked with Proactive about the company's two newly staked gold exploration projects in the United States, Quinn in Nevada and Drum in Utah.

Power explained that the Quinn project was identified through archival research and a proprietary database the company continues to mine for leads. The project, located on a shear cutting into volcanic rocks, appears to be a thermal target with potential depth.

Meanwhile, the Drum project in Utah was selected based on geophysical models that revealed deep crustal structures similar to those found in Carlin-style deposits. The company identified widespread Jasperoid mineralisation with low-grade gold of up to one gram per ton.

Both projects are early-stage, with Silver Range aiming to prepare them for drilling and seek joint venture partners. While gold prices have dipped slightly, Power remains confident in long-term demand and is positioning the company for when interest in gold exploration resurges.

Proactive: All right, welcome back inside our Proactive newsroom, and joining me now is Mike Power. He is the CEO of Silver Range Resources. Mike, it's great to see you again, how are you?

Mike Power: Very good. Thanks.

Good to have you along. Excited to talk today, the news out is exciting. You've staked some new projects, one in Nevada and one in Utah. I know you spend a lot of your time sort of roaming the earth trying to find these types of projects. So, let's talk about Quinn first. Tell me a bit about this one. This one's in Nevada, right?

Right. So, this one came out of some archival research. We had a database we purchased years ago, and we can just consistently mine it, and we keep our eye open on the ground that comes open. This one had been held for a little while, and it popped open, and we jumped on it in August. It was pretty good, and we wanted to get it ahead of the September claim renewal.

We know there was some high grade there. We had a historic sample up to 46g, and when we sampled that, we got up to 27g. It was a small little mining operation there, a cut into the hill. They were following a shear that ran into the hill and the city volcanics. It looks like a thermal target, which means it has legs — could go deep.

We don’t know much more about it right now. I just had one visit there to stake and sample it, and we’re looking forward to doing some more work, perhaps in the coming season.

Yeah, is that going to be mostly just boots on the ground type work? You're not planning on drilling, are you?

Oh, well, our M.O. is to dress the property up for drilling and find a partner. Sometimes we have a little small gas-powered drill we might take in and just do some shallow drilling, but generally we would prepare this project for drilling and look for a good partner who’s interested in moving it ahead.

All right, let's move to the beat of a new drum — that's the Drum property, as a matter of fact, which is in Utah. This is one of those — in the news release, you talk about the Carlin-like systems or Carlin-type systems, which I know get a lot of play. So maybe you can sort of explain that and what you see in this project?

Right. So this project has a lot of affinities to a Carlin target. What drew us into the area actually is we were doing a kind of 100,000ft view of the southwest U.S., and we were laying layers of seismic tomography one on another. These are models of deep fractures that go down into the upper mantle through the crust.

We found that a number of these seismic tomography models lined up in this area. So we said, well, let's have a little closer look at it. And when we did the research, that was a great target there that looks a lot like a Carlin target. It was looked at by Newmont and others.

So what’s involved here is it’s in a Cambrian limestone. There are Jasperoid — basically hematite-silica branches — that carry low-grade gold. They’re very widespread. We know there’s some high grade around there. We haven’t sampled it yet, but hopefully on our next pass. It looks very similar to the style of mineralization that drew the first geologists to the Carlin area.

These are kind of key characteristics of a Carlin deposit. You want to find these Jasperoid, ideally in some limestones, and then you’ve got a good-looking target. That’s what we have here. So we went out at the crack of dawn on September 1st, staked this thing, put it in initial position and did some sampling.

Basically every one of the Jasperoid we hit had some gold in it — up to about a gram. So nothing to knock your socks off yet, but it's very widespread. And we're going to see if there's something bigger, higher grade lurking around there. And that's the plan.

Yeah. Two gold projects here. Mike, I know there's been a bit of a fall-off on gold in the last little while, but it's still at a pretty good price. So I would imagine that gold is something that people are asking about and talking about.

Yeah. I mean, so the price goes from 4,200 or 4,300 bucks to 4,000 — listen, these are still stratospheric levels. And, you know, if this whole gold rally was just a flash in the pan, it'd have dropped back to 3,000 or 2,500, and there's no sign of that. Instead, it looks like it's just taken a break and things are going to move ahead when the rest of the world finally figures that out.

I think exploration companies are going to be pretty busy. But this could take a little while before people really believe it has long-term legs. In the meantime, we'll forge ahead. There’s actually a number of our projects — lots going on. And we hope to position ourselves for eventually the rest of the world waking up and thinking, hey, we really need to look at gold in Nevada, Utah, Arizona again.

Quotes have been lighted edited for style and clarity

Analyst’s Disclosure:I/we have a beneficial long position in the shares of ECC, NNN either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Beyond Saving, Philip Mause, and Hidden Opportunities, all are supporting contributors for High Dividend Opportunities. Any recommendation posted in this article is not indefinite. We closely monitor all of our positions. We issue Buy and Sell alerts on our recommendations, which are exclusive to our members.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

NEW YORK, Nov. 22, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 2025 and August 28, 2025, both dates inclusive (the “Class Period”), of the important January 9, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.

SO WHAT: If you purchased Telix securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Telix class action, go to https://rosenlegal.com/submit-form/?case_id=43778 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 9, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) defendants materially overstated the progress Telix had made with regard to prostate cancer therapeutic candidates; (2) defendants materially overstated the quality of Telix’s supply chain and partners; and (3) as a result, defendants’ statements about Telix’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Telix class action, go to https://rosenlegal.com/submit-form/?case_id=43778   or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

It's growing like wildfire, and it has many future opportunities.

Nu Holdings (NU +3.79%) lost some of its cachet when Berkshire Hathaway sold it off last year. However, it remains a top, market-beating stock with incredible long-term potential.

Nu stock is up 49% this year, and smart investors should continue paying attention.

Here are three reasons to buy Nu stock right now.

Image source: Nu.

1. It's adding customers at a high rate
Nu is an all-digital bank based in Brazil. It added 4.3 million customers in the 2025 third quarter and ended the quarter with 127 million customers, a 16% increase year over year. It already has 61% of the adult population in Brazil on the platform, and from here, it's expecting to grow revenue in this region by monetizing its clientele with more services.

However, the company still has tremendous opportunities in its newer markets of Mexico and Colombia. It has 13 million customers in Mexico, or 14% of the adult population, and it's already considered a market leader. In Colombia, it has nearly 4 million customers, or 10% of the population. These, including Brazil, are the three largest countries in Latin America by population, and Nu is taking a leading position in the digital banking revolution.

Its original premise was to capture the mass market, customers who have been closed out of the banking space because of high barriers to entry. It has moved on from there to capture market share in the affluent space as well. It already has a high overall engagement rate of 83%, including 85% in Brazil. That rate has remained high despite an influx of new customers, which could potentially dilute engagement.

Today's Change

(

3.79

%) $

0.58

Current Price

$

15.90

Average revenue per user is increasing
The strategy is to cross-sell and upsell more products and services, creating long-term opportunities and recurring revenue. Nu just released two new credit cards to help customers build credit history, for example, and it announced new partnerships with Amazon and Sea Limited's Shopee app to use its NuPay product in their marketplaces.

Average revenue per active customer (ARPAC) continues to grow every quarter, an impressive feat considering how many new customers there are every quarter. It topped $13 for the first time in the third quarter, up from $11 last year and $5 in 2021.

The newer regions are scaling even faster than Brazil's fast rise. ARPAC was $13.50 in Brazil in the third quarter and $12.50 in Mexico.

As the company makes more money per customer, it's becoming extremely profitable. It operates a low-cost platform with no physical branches, already cutting out a huge expense for most banks. Its cost to service has remained stable at $0.90 in the third quarter. Gross profit increased 34% year over year in the third quarter to $1.8 billion, and net income increased 39% (currency neutral) to $783 million. Total revenue also increased 39%.

It's planning to open in the U.S.
Perhaps the most exciting new update for Nu is that it's making some early plans to eventually open in the U.S. It's taking a step-by-step approach to growth, beginning with conquering Brazil, which it has already done successfully, and then moving into monetizing its customer base and branching out into new regions where it's easy to scale its model.

The next step is expanding into new regions, and it has its eyes on the U.S. as a new frontier. It applied for a U.S. bank charter a few weeks ago, stating that it will help serve its existing customers better, and "in the future, connect with those who share similar financial needs and could benefit from our products and services."

That's great news for the company and its shareholders. As Nu scales and expands, it's demonstrating phenomenal performance, and it has years of growth still ahead.

Rocket Lab NASDAQ: RKLB has been one of the most explosive names in the aerospace and defense sector over the past year. The company has transformed from a niche small-cap into a mainstream space-industry favorite, now carrying a roughly $23 billion market cap.

These companies will be fantastic long-term performers in any investment portfolio.

Growth stocks have a lot going for them. Growth stocks can compound revenue and earnings for long periods, leading to fantastic stock performance. That's as long as you buy at a reasonable price, of course. In fact, even though famous investors like Warren Buffett are deemed value investors, a lot of their huge winners come from companies with consistent revenue growth.

With this in mind, here are three growth stocks that even value investors will appreciate that you can buy and hold for the long term.

Image source: Getty Images.

Interactive Brokers: A brokerage taking market share
Interactive Brokers (IBKR 0.83%) is a digital-only stock and asset trading brokerage that serves advanced investors. It allows customers to trade in many different countries, currencies, commodities, and more, which you cannot get on most stock trading platforms, such as Robinhood. Serving individuals and professional teams, Interactive Brokers has built up a great brand in the brokerage space that convinces stock traders to switch to its service every quarter.

In the third quarter, Interactive Brokers customer accounts grew 32% year over year to 4.13 million. This is up from just 1 million at the end of 2020. Account growth correlates with revenue growth. Commission revenue was up 23% last quarter, with net interest income on client balances up 21%.

Today's Change

(

-0.83

%) $

-0.51

Current Price

$

61.05

The best part about Interactive Brokers is its incredible profit margins. Last quarter, it had a pre-tax profit margin of 79%, which is rare in a publicly traded company. A profit margin this high cannot expand forever, but Interactive Brokers is in a premier spot to keep stealing new clients and double or triple its active accounts over the next 10 years. With a current price-to-earnings ratio (P/E) of 30, the stock is trading at a reasonable price compared to its long-term growth potential.

Oscar Health: Near-term woes, long-term opportunity
A company that is not profitable today but still a fantastic long-term growth stock is Oscar Health (OSCR +3.45%). The upstart health insurer that targets the Affordable Care market (Obamacare) keeps growing users, but has faced stock price headwinds in 2025 due to growing costs impacting its insurance loss ratios and the potential for Obamacare subsidies to be severely scaled back in 2026.

Growing costs have impacted Oscar Health's profitability. A health insurer sets its rate annually for customers, which Oscar Health does, serving its 2 million members on the individual market.

Today's Change

(

3.45

%) $

0.45

Current Price

$

13.48

However, in 2025, insurers calculated wrong and underpriced their insurance premiums versus the utilization rates of customers, which led medical loss ratios to rise. Last quarter, Oscar Health's medical loss ratio -- which measures claims paid divided by premiums earned -- hit 88.5%, compared to 84.6% in the same quarter a year ago. This is clearly not ideal, but is something Oscar Health can quickly fix by repricing its plans for 2026, with it, along with other health insurers, planning to greatly increase rates to get back to profitability.

Depending on which way the political winds sway in the United States, extra subsidies for individual health insurance members may expire in 2026. This could put a dent in Oscar Health's paying members, but should only be a temporary headwind to the business, which has grown its members by close to 10x since 2019.

This year, Oscar Health will likely lose money. But if it can regain its trajectory on its medical loss ratio back to 80% (the maximum Obamacare insurers can earn) and keep decreasing its operating expenses as a percentage of revenue, the company will turn a profit. With $11 billion in revenue over the last 12 months, a measly 2.5% profit margin would get Oscar Health to $275 million in annual earnings in 2026, or a P/E ratio of just 14, compared to the current stock price.

Data by YCharts.

Nintendo: A resurgent gaming business
Readers will likely know this last company well. Nintendo (NTDOY +2.12%), the entertainment and gaming giant from Japan, owns characters such as Mario and Zelda, and has a licensing agreement with Pokémon.

This summer, Nintendo released its latest gaming hardware, the Nintendo Switch 2. It has begun selling like hotcakes, leading Nintendo to update its full fiscal year forecast for hardware sales from 15 million to 19 million (for the year ending in March). It also raised its full-year revenue and earnings guidance for shareholders.

Today's Change

(

2.12

%) $

0.44

Current Price

$

21.17

Growing hardware sales will help Nintendo grow its earnings again as the original Switch slowly loses popularity. New games are coming to the Nintendo Switch 2 from the Mario and Pokémon franchises, which should lead to high levels of overall game sales.

What's more, Nintendo is now consistently releasing visual content like movies. A new Mario movie is coming out in 2026, with a Zelda movie slated for 2027. This revenue diversification will feed back into the gaming business, hopefully building more fans of Nintendo around the globe.

We are just at the start of a multiyear growth story around the Nintendo Switch 2. With Nintendo stock down in recent months, now looks like a good time to hop back on the Mario train and add it to your portfolio, along with Interactive Brokers and Oscar Health.

This week in AI, the bubble keeps inflating despite fresh warnings, Google stages an AI comeback, and Chinese AI threatens Nvidia. Though fears around irrational AI spending used to be confined to skeptics, now even industry insiders like Google's Sundar Pichai and Demis Hassabis are voicing doubts.

SummaryMy portfolio is heavily concentrated on REITs.I have unique reasons for it.My approach is not as reckless as it may seem. Here is why.Black Friday Sale 2025: Get 20% Off mustafaU/iStock via Getty Images

If you have read my work here on Seeking Alpha, you will know that I am very bullish on Real Estate Investment Trusts, or REITs in short (VNQ).

I write weekly articles explaining why I

Analyst’s Disclosure:I/we have a beneficial long position in the shares of CPT; HTWSF either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Bitcoin has become a legitimate financial asset that investors can't ignore.

Bitcoin (BTC +1.10%) has been facing immense selling pressure lately. As of Nov. 18, the top cryptocurrency is down 26% from its peak, which was established in early October. However, the long-term thesis hasn't changed.

In my view, Bitcoin's price will triple to roughly $300,000 by 2030. There's a clear catalyst.

Image source: Getty Images.

Scarcity is the most important factor
There will only ever be 21 million Bitcoin units in circulation one day. This hard supply cap is the cryptocurrency's most attractive characteristic. And it goes against how the monetary system operates.

Over the past 15 years, the M2 money supply of the world's four largest central banks has expanded by 145%. This has coincided with rising debt levels. There is no end in sight to this worrying trend.

Combine a fixed-supply asset with ever-increasing levels of fiat currency, and it makes sense why Bitcoin's price has shot up historically.

Today's Change

(

1.10

%) $

922.67

Current Price

$

84522.00

Expect lower returns
Since mid-November 2020, Bitcoin has climbed 416% (as of Nov. 18). This translates to a superb 39% compound annual growth rate. While it's easy to be bullish, investors should still expect forward returns to be lower than what was achieved in the past.

Bitcoin is becoming a more mature asset, so the gains will naturally come down. However, seeing its price triple by 2030 is a totally realistic outcome.

Neil Patel has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bitcoin. The Motley Fool has a disclosure policy.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

The past few years have not been kind to real estate investors. Despite the Federal Reserve cutting interest rates, 30-year mortgage rates remain historically elevated, and major homebuilders are seeing steep declines.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Oracle stock price has suffered a major reversal as concerns about the artificial intelligence (AI) and its soaring debt remain. ORCL dropped to a low of $198, down by over 36% from its highest point this year.

Are new satellite developments a worrying sign for traditional broadband operators? Not so fast, say Citi analysts who see a “win-win” situation on the horizon.

Wall Street

getty

We contrarians follow Wall Street analysts because we like to fade their opinions!

When most say Buy, we are cautious. There is nobody left to upgrade these shares.

When they slap a Sell label, we are intrigued. So you’re saying the next rating change will be an upgrade?

These slippery suits rate most stocks Buys because, well, that’s the business. As we speak, 400 of the S&P 500 (!) is rated a Buy!

So let’s sift through the Holds and the Sells. Today we’ll sort through a four-pack yielding between 7.9% and 20.6%. We begin with a pair of real estate investment trusts (REITs), which are known for paying “really high” dividends.

Hated Dividends #1National Storage Affiliates Trust (NSA, 7.9% yield) is a self-storage REIT with 1,069 properties across 37 states and Puerto Rico. This is a recession-resistant industry. During boom times, people purchase—and stash—stuff. In downtimes, they downsize and need an extra place to stash that Crate & Barrel couch.

Self-storage stocks do weather booms and busts, however. The flow of “stuff” is not constant. Currently, NSA is dealing with a 20% pullback:

NSA Total Returns

Ycharts

MORE FOR YOU

NSA reported numerous issues in its most recent quarter, including lower earnings, core FFO, same store net operating income, and same store period-end occupancy. However, earnings from competitors like Public Storage (PSA) and Extra Space Storage (EXR) revealed similar issues, so this points to more of a challenging operating environment in the space than it does unique challenges for NSA, which historically has been a strong operator.

We discussed, but cautioned against, NSA as a hated stock earlier this year. And the situation, indeed, has deteriorated since then. Shares are down by 13%. The stock has picked up a few more Sell calls.

NSA’s multiple is down to 13-times FFO. But payout coverage has tightened, too. The company expects to earn $2.20 per share at the midpoint, while NSA is on pace to pay out $2.28 in dividends.

Hated Dividends #2Alexander’s (ALX, 8.5% yield) is a landlord with five (count ‘em, five) holdings. While technically an office REIT, its properties include retail and residential exposure, too. Needless to say, Alexander’s is extraordinarily concentrated, with tenant Bloomberg accounting for 60% of revenues over the first nine months of 2025.

Also worth noting: Vornado Realty Trust (VNO) not only owns roughly a third of this Big Apple real estate group, but it also manages it. That means ALX owes it annual management fees and occasionally development fees. And over the last quarter, Alexander’s entered an extension with Vornado on a $300 million loan encumbering 731 Lexington Ave., then failed to repay the loan by the extended maturity date in October. Now, Alexander’s is in discussions with the lenders about a potential loan restructuring.

Despite its issues, the stock is sitting on double-digit total returns in 2025. That’s better than the broader real estate sector, which is just over breakeven for the year.

But Wall Street still can’t get behind ALX, and the reason why might have more to do with its dividend than anything else.

2023: ALX paid $18 in dividends against $15.80 in funds from operations (FFO, an important metric of REIT profitability)2024: ALX paid $18 in dividends against $15.19 in FFO2025: ALX has paid out $13.50 in dividends against $9.84 in FFO through three quarters.Worse? That $9.84 in FFO is about 11% worse than at the same point last year, continuing a trend of declining funds from operations.

ALX Total Returns

Ycharts

That also points to a full valuation for ALX shares, which are trading at more than 16 times 2025’s annualized FFO.

Hated Dividends #3Robert Half (RHI, 9.0% yield) predominantly works in three areas: Contract Talent Solutions (placing temporary workers with companies), Permanent Placement Talent Solutions (helping companies recruit and land full-time workers) and Protiviti (consulting services for compliance, finance, HR, legal and more).

In short, its job is to put people into jobs. The problem? AI is coming for these jobs.

Robert Half wouldn’t have popped up on most dividend radars at the start of 2025—but in less than a year, its yield has ballooned from 3% then to 9% now. We can thank a nosedive in RHI shares, which are down 80% since peaking in 2022 and off by about 60% year-to-date, prompting more Sell calls (3) and Holds (6) than Buys (2).

RHI Total Returns

Ycharts

But the reason I’m even taking a look at Robert Half is that it might not be the doomed AI victim it seems.

First off: RHI’s fall started from a bubblicious peak. Remember: The post-COVID reopening set off a hiring spree that was so frenetic, several companies that have recently laid off employees claimed they overhired during that time. RHI shares were overcooked then and destined to fall amid the inevitable hiring moderation that followed.

This year? Hiring hasn’t just slowed; ADP recently estimated that U.S. companies were ditching more than 11,000 jobs per week through late October.

How much of this is due to a stumbling economy and tariff tumult, and how much of this can be chalked up to AI? Robert Half, at least, seems to think the artificial intelligence narrative is extremely overplayed.

“There were big studies by Stanford, Harvard, and Yale,” CEO Keith Waddell said during Robert Half’s third-quarter earnings call. “Stanford says AI impact is for early career entry-level people, that more experienced roles remain stable. Harvard says generative AI is reducing entry-level hiring while increasing reliance on senior talent. Yale says the broader labor market has not experienced any discernible disruption from generative AI. I guess my point would be as to impact to labor overall, impact to, for us, accounting and finance talent overall, we’ve seen very little impact.”

Robert Half is still facing significant issues regardless. Q4 guidance came up short. The macro picture is still uncertain. Dividend coverage is suddenly a problem, too. The company’s profits are expected to plunge by 45% this year, to $1.34 per share, before rebounding quite a bit to $1.79 per year. But aggressive growth in the dividend has brought the payout to 57 cents quarterly ($2.28 annually), which will outstrip earnings by quite a bit through at least the end of 2026, if estimates hold.

A sudden economic turn for the better could turn the 9%-yielding Robert Half into a turnaround monster. But Wall Street appears to be betting on the status quo.

Hated Dividends #4It’s hard to find many stocks yielding more than Cricut (CRCT, 20.6% yield), a craft-store heavyweight whose machines let users turn their ideas into professional-looking handmade goods such as T-shirts, mugs and interior decorations. But the company would also remind us it’s a “creativity platform” with software that integrates its machines with design apps (including its own Cricut Joy App) and a pair of subscription plans.

Cricut first grabbed my attention in 2024. It had been paid a few special dividends before, but in July, it kicked off a new semiannual dividend program alongside another large special distribution. It stood out because while most companies unfurl new dividends when the bottom line is growing, CRCT did so while its profits were flagging.

CRCT Total Returns

Ycharts

The last time I checked on Cricut (in May 2025), the stock had announced an even bigger special dividend, yielded 15%, and analysts were pretty sour on it.

A few months—and a nearly 25% decline later—it yields north of 20% and the pros downright hate it. Every analyst covering the stock says we should ditch it.

I wouldn’t tell that to Cricut’s fervent and loyal user base. In fact, the company itself has said that word-of-mouth is one of its strongest drivers of new users. Meanwhile, tariffs haven’t bitten as hard as expected, and the company is expected to expand its profits by more than 20% in 2025.

But even a great product doesn’t guarantee continued growth, especially when that product belongs to a niche like crafting. Revenues are expected to remain flat if not shrink a bit over the next couple of years. 2026 profits are projected to fall off a cliff. And if soft job markets lead to a subdued holiday shopping season (historically Cricut’s biggest quarter), the company could fall behind optimistic views for the full year.

Not to mention: The lion’s share of CRCT’s yield (about 16 points’ worth!) hinges on special distributions that simply aren’t guaranteed.

Brett Owens is Chief Investment Strategist for Contrarian Outlook. For more great income ideas, get your free copy his latest special report: How to Live off Huge Monthly Dividends (up to 7.6%) — Practically Forever.

Big Gains Are On The Way For These Marijuana Stocks

2 minute read

These 2 Marijuana Stocks Are The Better Options To See A Profit
The best way to invest in marijuana stocks is to build a trading plan. But what does this look like, and where do we begin? To start research and learn about the legal sector and the companies within it. Learn which ones are publicly traded and how they have performed over the last year. To find out which marijuana stocks are performing well as a business. The better a company is doing outside of the market, the better the odds of seeing it trade better.

Yet for some time, legal battles and regulatory concerns have presented challenges to legal operators. These challenges have led to a drop in trading, which makes it easier to find top marijuana stocks to buy. Having a good strategy and an understanding of what is occurring in the sector that could affect your investments is important.

Yes, cannabis stocks are a highly volatile sector with unpredictable patterns. But when the time comes to take profits, your plan of action could be the means of why you’re up. 2026 is shaping up to be a big year in cannabis that could have much more for the investors and shareholders. The companies below are just a few top cannabis stocks to watch that could turn a profit this year.

Marijuana Stocks For Better Trading In 2026

GrowGeneration Corp. (NASDAQ:GRWG)
Greenlane Holdings, Inc. (NASDAQ:GNLN)

GrowGeneration Corp.
GrowGeneration Corp., through its subsidiaries, owns and operates retail hydroponic and organic gardening stores in the United States.

It operates through two segments, Cultivation and Gardening, and Storage Solutions. Back in early November 2025, the company reported its Q3 2025 results.

Q3 2025 Financial Results.

Net sales of $47.3 million, up 15.4% quarter-over-quarter;
Proprietary brand sales as a percentage of Cultivation and Gardening net sales increased to 31.6% compared to 23.8% in the third quarter of 2024;
Gross profit margin of 27.2%, compared to 21.6% for the third quarter of 2024;
Store and other operating expenses declined approximately 27.8% to $7.2 million, compared to $10.0 million for the same period in the prior year;

[Read More] 3 Marijuana Stocks To Invest In During This Year

Greenlane Holdings, Inc.
Greenlane Holdings, Inc. engages in the development and distribution of cannabis accessories, vape devices, and lifestyle products in the United States, Canada, Europe, and Latin America. The company, in more recent news, has reported its Q3 2025 financial results.

[Read More] 3 Of The Best Marijuana Stocks To Buy For Possible Gains In 2026

Key Mentions Third Quarter 2025 Financial Results

Bruce Linton previously led Canopy Growth Corporation to a $15B market capitalization.
Billy Levy, a serial entrepreneur and capital markets executive with a history of building, scaling, and exiting companies

Formed a Digital Assets Committee in October 2025, comprised of Mr. Levy and
Mr. Linton, with Mr. Linton serving as chair.
Raised over $110 million in capital and digital assets through an October 23, 2025, private placement offering

MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | [email protected]

Bitcoin, the flagship cryptocurrency, has been facing a tumultuous period, with experts predicting further volatility in the coming months. As of early November 2025, the cryptocurrency's value has experienced significant fluctuations, sparking a debate over its future stability and growth potential.

Aerodrome, the leading decentralized exchange on Base blockchain, has raised an alarm about a potential DNS hijacking incident that could put user funds at risk. This security warning comes as the platform investigates suspicious activity affecting its main domain.

Spot crypto exchange-traded funds (ETFs) saw a rebound at the end of the week, with all Bitcoin, Ether and Solana funds seeing inflows after a week of volatility and downturns.

On Friday, spot Bitcoin (BTC) ETFs attracted $238.4 million in net inflows after a wave of heavy redemptions the day before. BlackRock’s IBIT drove the turnaround with $108 million, while smaller contributions from BITB, ARKB, and BTCO helped lift sentiment. Even Grayscale’s GBTC, long pressured by outflows, added $61.5 million, according to data from Farside Investors.

The recovery came after a bruising $903 million outflow on Thursday,  the biggest outflow day in November and one of the largest single-day outflows since the products were launched in January 2024.

During the day, redemptions hit nearly every issuer, including IBIT with a loss of $355.5 million, FBTC with $190.4 million pulled, and GBTC with $199.4 million in outflows.

Bitcoin ETFs attract $238 million. Source: Farisde InvestorsEther funds snap 8-day outflow streakAfter eight consecutive sessions of redemptions, Ether (ETH) ETFs broke their losing streak with $55.7 million in inflows on Friday, powered largely by Fidelity’s FETH, which brought in $95.4 million.

The reversal followed a punishing stretch from Nov. 11–20, when Ethereum funds shed a combined $1.28 billion, one of the longest and deepest red waves since their launch.

Meanwhile, Solana (SOL) ETFs continue to outperform the broader altcoin market. Since launch, the five Solana funds have gathered $510 million in net inflows, led overwhelmingly by Bitwise’s BSOL with $444 million. The group has now logged a 10-day inflow streak.

Ether traders tentatively add longs Ether slumped sharply this week, dropping 15 percent between Wednesday and Friday and liquidating 460 million dollars in leveraged long positions.

However, despite the decline and a total drawdown of 47 percent since the August all-time high, derivatives data shows top traders slowly adding long exposure. Futures funding rates have risen from four percent to six percent, indicating early signs of stabilization even though bullish demand remains weak.

Magazine: 2026 is the year of pragmatic privacy in crypto — Canton, Zcash and more

Tron (TRX) has been on a bear trend in recent weeks, with a 5.43% drop in the last 7 days, and  a 14.52% drop in the last 30 days, trading at $0.2768. In recent developments, TRON begins a new chapter after closing USDJ, its long-running algorithmic stablecoin. The 1 USDJ = 1.5532 TRX redemption rate confirms a clean exit path for holders. The wind-down marks the end of an era that shaped TRON’s early DeFi identity. The chain now reallocates resources toward models backed by collateral, like USDD and USDT. This shift aligns with global demand for safer stablecoin structures.

USDJ once played a key role in TRON’s DeFi push, but its liquidity faded as the ecosystem embraced external stablecoins. The new redemption phase clears lingering uncertainty and simplifies the system for new users. It also signals TRON’s strategic maturity. Is this exactly what TRON needed before scaling new products? Many analysts argue yes.

USDT Dominance Reinforces TRON’s Market LeadershipTRON’s dominance in stablecoin circulation stands out. The network now hosts over $78.5 billion in USDT supply, representing more than 60% of all USDT in existence. This dynamic reflects real usage at global scale, not speculative hype.

Source: X

Real-world adoption metrics show massive traction:

$775.2B monthly transaction volume

76.4M monthly transfers

Near-zero transfer fees

Sub-second finality

These figures capture why TRON leads markets in remittances, emerging-economy commerce, and high-frequency transfer systems. For millions, TRC-20 USDT has become the default digital dollar. Ethereum and L2s cannot match these costs in high-volume scenarios.

Why does this matter for TRX? High settlement flows reinforce the token’s utility, deepen liquidity, and increase demand for network resources during peak usage cycles.

A Stronger Infrastructure BackboneTRON maintains steady uptime, predictable fees and a performance profile suited for regions with tight economic conditions. Developers rely on this stability. Protocols like JustLend, SunSwap, WINkLink and JustStables anchor billions in TVL.

Tether’s ongoing preference for the chain strengthens confidence. New USDT issuance often appears on TRON first. The cycle feeds itself:

More USDT supply

Higher liquidity

More protocol activity

Higher demand for TRX

It’s a flywheel that keeps turning.

Where TRX Stands: Key Technical LevelsTRX bounced at the long-term support band near $0.28. Buyers stepped in fast. The structure now forms a narrowing wedge with higher lows. Watch the $0.280–$0.285 cluster, a vital area that could set the next trend leg.

Source: X

Technical structure:Pattern: Break + retest bounce

Bias: Short-term recovery

Target: $0.31 if strength continues

A weak rebound could send TRX back to lower support before any climb. A break above $0.31 would shift momentum toward $0.34 and $0.37.

Prediction TablePeriodMinimumAverageMaximumDecember 2025$0.26$0.28$0.31November 2025$0.25$0.27$0.302025 Full Year$0.23$0.30$0.37The Outlook for 2025TRX moves into 2025 with two powerful forces. The first is unmatched stablecoin dominance that drives consistent demand. The second is a DeFi realignment based on reliable collateral models. These trends build confidence for long-term sustainability.

Short-term sentiment depends on TRX holding the wedge structure. Long-term sentiment depends on maintaining global leadership in stablecoin transfers. Both forces point toward steady growth if adoption continues. The market now watches TRX’s behavior near support to confirm its next breakout phase.